JP2017507145A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507145A5
JP2017507145A5 JP2016553402A JP2016553402A JP2017507145A5 JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5 JP 2016553402 A JP2016553402 A JP 2016553402A JP 2016553402 A JP2016553402 A JP 2016553402A JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5
Authority
JP
Japan
Prior art keywords
delivery system
substance delivery
matrix
polymeric material
anabolic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553402A
Other languages
English (en)
Japanese (ja)
Other versions
JP6510547B2 (ja
JP2017507145A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053645 external-priority patent/WO2015124739A1/en
Publication of JP2017507145A publication Critical patent/JP2017507145A/ja
Publication of JP2017507145A5 publication Critical patent/JP2017507145A5/ja
Application granted granted Critical
Publication of JP6510547B2 publication Critical patent/JP6510547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553402A 2014-02-20 2015-02-20 Fgf−18を含むインプラント Active JP6510547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000598 2014-02-20
EP14000598.4 2014-02-20
PCT/EP2015/053645 WO2015124739A1 (en) 2014-02-20 2015-02-20 Implant comprising fgf-18

Publications (3)

Publication Number Publication Date
JP2017507145A JP2017507145A (ja) 2017-03-16
JP2017507145A5 true JP2017507145A5 (enExample) 2018-02-22
JP6510547B2 JP6510547B2 (ja) 2019-05-08

Family

ID=50151086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553402A Active JP6510547B2 (ja) 2014-02-20 2015-02-20 Fgf−18を含むインプラント

Country Status (24)

Country Link
US (1) US10086112B2 (enExample)
EP (1) EP3107592B1 (enExample)
JP (1) JP6510547B2 (enExample)
KR (1) KR102421950B1 (enExample)
CN (1) CN106232154A (enExample)
AR (1) AR099556A1 (enExample)
AU (1) AU2015220785B2 (enExample)
BR (1) BR112016018681B1 (enExample)
CA (1) CA2938796C (enExample)
DK (1) DK3107592T3 (enExample)
ES (1) ES2698117T3 (enExample)
HR (1) HRP20181573T1 (enExample)
IL (1) IL247106B (enExample)
LT (1) LT3107592T (enExample)
MX (1) MX368946B (enExample)
NZ (1) NZ723177A (enExample)
PL (1) PL3107592T3 (enExample)
PT (1) PT3107592T (enExample)
RS (1) RS58138B1 (enExample)
RU (1) RU2700414C2 (enExample)
SG (1) SG11201606697YA (enExample)
SI (1) SI3107592T1 (enExample)
WO (1) WO2015124739A1 (enExample)
ZA (1) ZA201605667B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105103654B (zh) 2013-02-14 2017-06-23 纳米帕雷尔股份有限公司 纳米纤维混合毛毡
AR099510A1 (es) 2014-02-20 2016-07-27 Merck Patent Gmbh Régimen de dosaje del compuesto fgf-18
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
RS63292B1 (sr) 2017-09-29 2022-06-30 Merck Patent Gmbh Inflamatorni biomarkeri za predviđanje responsivnosti na jedinjenje fgf-18
SI3687558T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Presnovni biooznačevalci za napovedovanje odzivnosti na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CN117187255B (zh) * 2023-11-07 2024-01-30 北京大学第三医院(北京大学第三临床医学院) 编码FGF18或rhFGF18的mRNA及其在骨关节炎治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
EP0896825B1 (en) * 1997-08-14 2002-07-17 Sulzer Innotec Ag Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
KR100380119B1 (ko) * 2001-04-19 2003-04-11 한국항공우주연구원 이원화된 통신속도 적응형 베이스 밴드 스위칭 위상시프트 키잉 장치
EP1273365A1 (fr) * 2001-07-06 2003-01-08 Recherche Et Developpement Du Groupe Cockerill Sambre Outils rotatifs pour le perçage en ligne de produits profiles
WO2004032849A2 (en) * 2002-10-07 2004-04-22 Zymogenetics, Inc. Methods of administering fgf18
US8852240B2 (en) * 2004-10-25 2014-10-07 Kieran Murphy, Llc Methods and compositions for fostering and preserving bone growth
EP1828239B1 (en) * 2004-12-10 2011-08-24 ZymoGenetics, Inc. Fgf18 production in prokaryotic hosts
DK2054050T3 (da) * 2006-08-25 2012-09-03 Ares Trading Sa Behandling af brusksygdomme med FGF-18
WO2010102266A1 (en) * 2009-03-05 2010-09-10 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
US8431399B2 (en) * 2010-03-02 2013-04-30 Taipei Medical University Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro
US10130687B2 (en) * 2011-01-05 2018-11-20 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
JP5990720B2 (ja) * 2011-02-22 2016-09-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨再生及び/又は軟骨再生に使用するためのナノリザーバー技術
SG11201604972TA (en) * 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in alginate/collagen hydrogels
AR099510A1 (es) 2014-02-20 2016-07-27 Merck Patent Gmbh Régimen de dosaje del compuesto fgf-18
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.

Similar Documents

Publication Publication Date Title
JP2017507145A5 (enExample)
RU2016137291A (ru) Имплантат, содержащий fgf-18
JP2014139220A5 (enExample)
MX384527B (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
MX376585B (es) Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
JP2017512194A5 (enExample)
JP2016517888A5 (enExample)
JP2017501140A5 (enExample)
JP2017507142A5 (enExample)
SG10201903210WA (en) Sunitinib Formulations and Methods for Use Thereof in Treatment of Ocular Disorders
JP2017522288A5 (enExample)
RU2016137292A (ru) Схема применения соединения fgf-18
JP2017105861A5 (enExample)
WO2021034958A3 (en) Materials for delivery of tetherable proteins in bone implants
NZ599930A (en) Pharmaceutical compositions for the stimulation of stem cells.
JP2018521643A5 (enExample)
JP2017513809A5 (enExample)
JP2017105862A5 (enExample)
JP2017519568A5 (enExample)
JP2017105859A5 (enExample)
HRP20180061T1 (hr) Indolkarbonitrili kao selektivni modulatori androgenskih receptora
JP2017523149A5 (enExample)
NZ729628A (en) Methods for the treatment of peri-implantitis
JP2015515974A5 (enExample)
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting